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Every	COVID-19	patient	should	be	able	to	join	a
randomised	clinical	trial
Yang	Chen	(UCL	&	LSE)	and	Bogdan	Enache	(LSE)	are	two	clinicians	on	the	frontline	of	the	pandemic.	They
explain	their	concern	that	evidence-based	medicine	is	being	jettisoned	in	favour	of	guidelines	drawn	up	on	the	basis
of	expert	opinion	and	case	series,	and	make	the	case	for	every	COVID-19	patient	to	be	offered	the	opportunity	to
join	a	randomised	clinical	trial.
As	two	aspiring	clinical	researchers	who	met	at	LSE,	we	feel	that	the	school	motto	Rerum	cognoscere	causas	–	“to
know	the	causes	of	things”	–	accurately	describes	the	challenge	of	delivering	a	global,	evidence-based	response	to
COVID-19.
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We	are	clinicians	by	background,	but	during	our	Executive	MSc	in	Health	Economics,	Outcomes	and	Management
in	Cardiovascular	Sciences,	we	have	been	afforded	a	new	vantage	point	and	perspective	on	the	healthcare
response.
On	the	frontline,	we	have	both	seen	a	striking	unity	of	human	spirit,	resilience	and	teamworking	that	is	in	stark
contrast	to	the	divergent	clinical,	research	and	health	policy	responses.	We	believe	that	the	familiar	concepts	of
evidence-based	medicine	(EBM)	and	leadership	warrant	greater	collective	and	explicit	emphasis	so	that	our
patients	can	receive	the	highest	quality	of	care	in	these	difficult	times.
We	have	sadly	observed	many	examples	where	EBM	has	not	been	followed	judiciously	enough.	While	treating
COVID-19	patients,	we	have	anecdotally	seen	and	heard	from	fellow	colleagues	and	professionals	an	urge	to	follow
official	guidelines	or	protocols	to	help	determine	which	treatments	to	give.	This	is	a	natural	instinct	–	in	times	of
uncertainty,	decision-making	feels	safer	when	following	a	document	written	by	an	authoritative	and	respected
source.	However,	we	are	concerned	in	the	faith	being	placed	in	guidelines	currently	based	on	evidence	from
cohorts,	case	series	or	expert	opinion,	drawn	from	first	principles	and	biological	plausibility.
In	dealing	with	unpredictable	workloads	and	stress,	our	contention	is	that	no	further	undue	burden	should	be	placed
on	clinicians	to	decide	what	treatment	is	‘best’	depending	on	which	local,	national	or	international	guideline	or
expert	they	follow.	The	principles	of	EBM	should	take	centre	stage.	To	handle	clinical	equipoise	appropriately,
randomisation	of	treatment	as	part	of	a	clinical	trial	should	be	the	only	way	to	arrive	at	unbiased	answers,	releasing
precious	time	for	doctors	and	nurses	to	concentrate	on	getting	the	fundamentals	correct.
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We	therefore	believe	that	there	is	an	urgent	unmet	need	for	each	and	every	COVID-19	patient,	regardless	of	their
geography,	to	be	offered	enrolment	into	a	pragmatic	randomised	clinical	trial	(RCT).	Instead,	as	a	community,	we
have	knowingly	delivered	unproven	treatments	in	a	non-trial	setting.	Good	intentions	do	not	excuse	bad	science.
More	worryingly,	there	have	been	anecdotes	of	patients	who	have	refused	to	take	part	in	a	clinical	trial	for	fear	of
receiving	perceived	inferior	treatment,	or	even	those	who	have	taken	matters	into	their	own	hands.	The	value	of
EBM	needs	concerted	and	compelling	messaging	from	our	academic	and	clinical	communities,	amplified	not	just	in
research	literature	but	also	on	mainstream	and	social	media	platforms.
On	a	more	positive	note,	there	is	no	lack	of	will	or	desire	to	help	from	members	of	our	broad	community	and	so	the
challenge	will	be	on	how	to	harness	this	energy	and	use	it	to	its	greatest	effect.	However,	currently	the	energy
seems	unfocused	with	too	many	individuals	or	small	groups	trying	to	‘be	the	leader.’	For	example,	the	number	of
systematic	reviews	registered	on	PROSPERO	featuring	COVID-19	stands	at	over	900	at	the	time	of	writing.	How
many	of	these	overlap	and	how	many	will	lead	to	informative,	useful	conclusions?	What	is	the	opportunity	cost	and
research	waste	of	unbounded	efforts	from	enthusiastic	amateurs	and	dedicated	professionals?
This	lack	of	coordination	also	seems	to	affect	research	from	a	basic	science	perspective.	In	the	UK,	a	study	aiming
to	better	understand	the	natural	history	of	the	virus	and	immunity	is	underway,	but	how	many	laboratories	have
joined	together	to	create	a	truly	global	bioresource	that	may	arrive	at	critical	answers	faster	and	more	accurately?
As	two	early-career	clinicians,	we	must	ask:	why	is	this	research	not	on	a	larger	scale?	And	what	central	leadership
mechanism	is	needed,	along	with	active	followership,	in	order	to	better	coordinate	our	response?
In	a	political	vacuum,	the	World	Health	Organization	(WHO),	would	appear	to	be	perfectly	positioned	to	take
international	leadership.	The	responsibility	of	ensuring	patients	in	different	healthcare	systems	are	entered	into
clinical	trials	and/or	appropriate	bioresources	could	then	rest	with	such	a	central	body,	thus	ensuring	no	overlap	or
duplication	of	work	from	smaller	centres.	There	is	already	precedence	for	this	given	in	WHO’s	SOLIDARITY	trial,	an
international	RCT	testing	four	different	treatment	regimens.
More	broadly,	given	that	countries	have	so	far	taken	a	heterogenous	approach	to	policies	such	as	social	distancing
and	mask-wearing,	could	the	WHO	additionally	coordinate	randomised	studies	of	entire	healthcare	policies	given
the	apparent	equipoise?	In	normal	times,	such	RCTs	would	be	prohibitive	to	conduct.	However	in	the	time	of
COVID-19,	the	case	should	be	made	far	more	strongly	that	currently,	any	intervention	should	only	be	pursued	in	the
context	of	an	RCT.
Lastly,	how	do	we	better	coordinate	messaging	as	a	community,	and	calibrate	writing	style	and	tone	to	be
commensurate	with	the	intended	impact	of	our	message?	If	opinion	and	stories	trump	nuance	and	complex	study
designs	–	should	leaders	in	local	departments	and	national	boards	be	directing	more	attention	to	identifying	the
most	media-savvy	clinicians	and	scientists?	In	both	our	undergraduate	and	postgraduate	training,	we	have
developed	in	an	environment	where	the	art	of	communication	is	becoming	as	important	as	the	science	of
generating	EBM.	Does	nominating	non-traditional	leaders	as	public	advocates	of	EBM	represent	a	paradigm	shift
that	even	COVID-19	cannot	compel…	and	if	so,	what	does	this	say	about	medical	hierarchies?
Once	the	pandemic	is	over,	there	is	an	opportunity	for	our	healthcare	response	to	leave	an	indelible	mark	that	is
positive	and	framed	around	change	and	renewal.	Our	perspective	is	that	greater	leadership	and	use	of	EBM,	in
order	to	offer	a	coordinated	response,	should	be	the	policy	not	just	for	COVID-19	but	for	the	practise	of	medicine
moving	forward.
In	an	age	of	heightened	patient,	public	and	societal	need,	and	a	world	of	many	heroes,	we	are	reminded	of	the
words	of	one	of	ours,	the	late	Doug	Altman:	We	need	less	research,	better	research	and	research	done	for	the	right
reasons.
This	post	represents	the	views	of	the	authors	and	not	those	of	the	COVID-19	blog,	not	LSE.
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